81.4 F
New York
81.4 F
New York
Sunday, July 25, 2021

Inequities in cancer genomics undercut precision medicine

- Advertisement -spot_img

Translating the promise of cancer genomics into health equity has not yet become a reality, two experts write in a commentary published recently in Cancer Cell. Instead, the racial gaps in cancer mortality have only slightly narrowed since the human genome was sequenced two decades ago, they note, and in preventable cancers such as breast and colorectal cancer, socioeconomic inequalities in cancer deaths are widening.

DNA data are certainly being used to precisely target cancer and other diseases with treatments developed to block genetic variants that give rise to malignancy. But that remarkable precision depends on the populations whose genetic sequences have been deciphered. For the most part, existing genetic data comes from people of European ancestry. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Disclaimer: This article is for informational purposes only. It is not a direct offer or solicitation of an offer to buy or sell, or a recommendation or endorsement of any products, services, or companies. OTCBBStockNews.com does not provide investment, tax, legal, or accounting advice. Neither the company nor the author is responsible, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any content, goods or services mentioned in this article.

- Advertisement -spot_img
Lena Berryhttps://otcbbstocknews.com
Lena Berry is the executive editor of OTC BB Stock News. Apart from managing the large team of writers, you will find her writing about various topics.
spot_img

Latest news

- Advertisement -spot_img

Related news

- Advertisement -spot_img
Subscribe to our newsletter.We never spam.